美股IPO·2025-11-08 08:19Core Viewpoint - Pfizer successfully acquired the weight loss startup Metsera for $10 billion, defeating Novo Nordisk with a premium of 159%, marking a strategic breakthrough in the $100 billion weight loss drug market [1][3][9] Group 1: Acquisition Details - Pfizer's final offer for Metsera was $86.25 per share, consisting of an initial cash payment of $65.60 and potential milestone payments of up to $20.65 [3] - The acquisition was approved by the FTC, providing certainty for the transaction, unlike Novo Nordisk's proposal which faced regulatory scrutiny [3][9] - Metsera's stock price surged approximately 150% since Pfizer's initial announcement of the acquisition intent [4] Group 2: Strategic Implications - The acquisition is crucial for Pfizer, which is facing declining revenues from COVID-related products and failed attempts at developing its own weight loss drugs [8] - Novo Nordisk aimed to enhance its competitiveness in the weight loss market through the acquisition of Metsera, amid pressure from competitors like Eli Lilly [8] - The global weight loss drug market is projected to reach $100 billion by 2030, with next-generation drugs expected to offer better efficacy and fewer side effects [9] Group 3: Market Dynamics - The competition among pharmaceutical giants is intensifying, with both Pfizer and Novo Nordisk seeking to secure a foothold in the lucrative weight loss drug sector [1][9] - Metsera, founded in 2022, focuses on developing next-generation weight loss drugs, with a pipeline that could outperform existing treatments [9]